You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
Biological Activity for ZLD 1039
ZLD 1039 is a potent and selective EZH2 inhibitor (IC50 = 5.6 nM). Displays selectivity for EZH2 over a panel of HMTs (inhibition less than 30% at 16 μM). Blocks H3K27 methylation in breast cancer cell lines. Induces tumor regression and metastasis in breast cancer xenograft-bearing mice. Reactivates silenced tumor suppressors in vivo. Orally bioavailable.
Technical Data for ZLD 1039
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for ZLD 1039
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|DMSO||12.26||20 with gentle warming|
|ethanol||12.26||20 with gentle warming|
Preparing Stock Solutions for ZLD 1039
The following data is based on the product molecular weight 612.8. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.2 mM||8.16 mL||40.8 mL||81.59 mL|
|1 mM||1.63 mL||8.16 mL||16.32 mL|
|2 mM||0.82 mL||4.08 mL||8.16 mL|
|10 mM||0.16 mL||0.82 mL||1.63 mL|
References for ZLD 1039
References are publications that support the biological activity of the product.
Song et al (2016) Corrigendum: Selective inhibition of EZH2 by ZLD1039 blocks H3K27methylation and leads to potent anti-tumor activity in breast cancer. Sci.Rep. 29 24893 PMID: 27128979
If you know of a relevant reference for ZLD 1039, please let us know.
View Related Products by Product Action
Keywords: ZLD 1039, ZLD 1039 supplier, ZLD1039, Potent, selective, EZH2, inhibitors, inhibits, orally, bioavailable, H3K27, methylation, 5847, Tocris Bioscience
Citations for ZLD 1039
Citations are publications that use Tocris products.
Currently there are no citations for ZLD 1039. Do you know of a great paper that uses ZLD 1039 from Tocris? Please let us know.
Reviews for ZLD 1039
There are currently no reviews for this product. Be the first to review ZLD 1039 and earn rewards!
Have you used ZLD 1039?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Epigenetics Scientific Review
Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.
Stem Cells Scientific Review
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Cancer Metabolism Poster
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
Epigenetics in Cancer Poster
This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.